IRIS
DE PLACIDO, PIETRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.105
EU - Europa 1.772
NA - Nord America 1.418
SA - Sud America 277
AF - Africa 48
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 5.622
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.342
SG - Singapore 1.083
RU - Federazione Russa 834
CN - Cina 498
IT - Italia 456
BR - Brasile 216
HK - Hong Kong 168
VN - Vietnam 158
DE - Germania 155
NL - Olanda 75
IN - India 69
FI - Finlandia 53
GB - Regno Unito 49
FR - Francia 46
CA - Canada 45
KR - Corea 33
AR - Argentina 32
CI - Costa d'Avorio 27
MX - Messico 19
PL - Polonia 17
ES - Italia 15
PK - Pakistan 12
ZA - Sudafrica 12
JP - Giappone 11
UA - Ucraina 11
CZ - Repubblica Ceca 10
SE - Svezia 10
IQ - Iraq 9
BD - Bangladesh 8
BE - Belgio 8
ID - Indonesia 8
AT - Austria 7
EC - Ecuador 7
VE - Venezuela 7
IR - Iran 6
TR - Turchia 5
AL - Albania 4
CL - Cile 4
IE - Irlanda 4
MY - Malesia 4
PH - Filippine 4
RS - Serbia 4
AE - Emirati Arabi Uniti 3
CR - Costa Rica 3
GR - Grecia 3
KH - Cambogia 3
LT - Lituania 3
NP - Nepal 3
PY - Paraguay 3
UY - Uruguay 3
UZ - Uzbekistan 3
AZ - Azerbaigian 2
BO - Bolivia 2
CY - Cipro 2
JM - Giamaica 2
KZ - Kazakistan 2
MN - Mongolia 2
PE - Perù 2
TH - Thailandia 2
AF - Afghanistan, Repubblica islamica di 1
AU - Australia 1
BB - Barbados 1
BF - Burkina Faso 1
BS - Bahamas 1
BW - Botswana 1
BY - Bielorussia 1
BZ - Belize 1
CO - Colombia 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EG - Egitto 1
GT - Guatemala 1
HR - Croazia 1
HU - Ungheria 1
IL - Israele 1
IS - Islanda 1
KE - Kenya 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
MA - Marocco 1
MC - Monaco 1
MD - Moldavia 1
NG - Nigeria 1
NI - Nicaragua 1
PA - Panama 1
RO - Romania 1
SA - Arabia Saudita 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
TW - Taiwan 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 5.622
Salva come PNG Salva come JPEG
Città #
Singapore 535
Hefei 195
Moscow 195
Hong Kong 168
Ashburn 164
Naples 140
Chandler 136
Beijing 134
Santa Clara 102
Dallas 91
Munich 85
Amsterdam 60
Los Angeles 52
Ho Chi Minh City 48
New York 41
Hanoi 35
Kochi 34
Seoul 32
Turku 31
Millbury 29
Lawrence 26
Buffalo 25
Boston 22
Redondo Beach 22
Rome 22
Pune 21
São Paulo 21
Napoli 19
Des Moines 17
Helsinki 17
The Dalles 17
Frankfurt am Main 15
Milan 15
Nuremberg 15
Orem 14
Ottawa 14
Mexico City 13
Seattle 13
Casoria 12
Denver 12
Montreal 12
Poplar 12
Toronto 12
Warsaw 11
Brooklyn 10
Tokyo 10
Wilmington 10
Belo Horizonte 9
Haiphong 9
London 9
Da Nang 8
Dong Ket 8
Houston 8
Johannesburg 8
Manchester 8
Düsseldorf 7
Stockholm 7
Brno 6
Chicago 6
Formia 6
Lauterbourg 6
Massa di Somma 6
Redwood City 6
Turin 6
Vienna 6
Atlanta 5
Biên Hòa 5
Boardman 5
Bologna 5
Borgomanero 5
Falkenstein 5
Lappeenranta 5
Phoenix 5
Porto Alegre 5
Rio de Janeiro 5
Shanghai 5
Baghdad 4
Chennai 4
Fairfield 4
Fucecchio 4
Kortrijk 4
Kronberg 4
Lahore 4
Olomouc 4
Pomigliano d'Arco 4
Portici 4
Ribeirão Preto 4
Salerno 4
Salt Lake City 4
Salvador 4
Sciacca 4
Tirana 4
Veroli 4
Ankara 3
Ardabil 3
Belford Roxo 3
Botucatu 3
Brasília 3
Brussels 3
Bắc Giang 3
Totale 3.009
Salva come PNG Salva come JPEG
Nome #
Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-Line Sunitinib (QUASAR): Results of a Phase I Trial 150
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: A survey of young oncologists 148
CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors. 144
Impaired Seroconversion After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA Vaccine in Patients With Thymic Epithelial Tumors 139
Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis 138
A New Horizon of Liquid Biopsy in Thymic Epithelial Tumors: The Potential Utility of Circulating Cell-Free DNA 138
Incidence of fatigue and low-dose corticosteroid use in prostate cancer patients receiving systemic treatment: a meta-analysis of randomized controlled trials 137
Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review. 136
Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette–Guérin after transurethral resection of the bladder tumor 135
The Never-Ending History of Octreotide in Thymic Tumors: A Vintage or A Contemporary Drug? 133
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer 131
Prevalence of Sarcopenia in Women with Breast Cancer 130
Mechanisms of resistance to mTOR inhibitors 126
Shifting from a Biological-Agnostic Approach to a Molecular-Driven Strategy in Rare Cancers: Ewing Sarcoma Archetype 123
Safety and immunogenicity of the COVID-19 vaccine BNT162b2 for patients with breast and gynecological cancer on active anticancer therapy: Results of a prospective observational study 121
FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules 120
Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era 119
Use of folfirinox or nab-paclitaxel plus gemcitabine for the treatment of locally advanced pancreatic adenocarcinoma: A single institution observational study 119
Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study 118
Extraskeletal Ewing's sarcoma of the mediastinum: Case report 117
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI) 115
Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis 115
A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer 115
A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapy 114
Inadequate health-related quality of life assessment and reporting in phase III clinical trials of immune checkpoint inhibitors in solid cancers: a systematic review 113
Insight on the Role of Leptin: A Bridge from Obesity to Breast Cancer 112
Assessment of Total, PTEN–, and AR-V7+ Circulating Tumor Cell Count by Flow Cytometry in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide 112
BRAF Gene and Melanoma: Back to the Future 109
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis 107
Tumour microenvironment and immune evasion in EGFR addicted NSCLC: Hurdles and possibilities 106
Serum biomarkers of inflammation and vascular damage upon SARS-Cov-2 mRNA vaccine in patients with thymic epithelial tumors 103
Central obesity, body mass index, metabolic syndrome and mortality in Mediterranean breast cancer patients 103
DLL3 as a potential diagnostic and therapeutic target in neuroendocrine neoplasms: A narrative review 102
Exploring the interplay between Kaposi's sarcoma and SARS‐CoV‐2 infection: A case series and systematic review 100
COVID-19 in patients with thymic epithelial tumors with or without Good's syndrome: a single-center retrospective study 100
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study 100
FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study 100
Corrigendum to 'Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)': [ESMO Open Volume 6, Issue 2, April 2021, 100054] 96
Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671) 94
The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer 93
Endocrine‐based treatments in clinically‐relevant subgroups of hormone receptor‐positive/her2‐negative metastatic breast cancer: Systematic review and meta‐analysis 91
Case report: Potential role of immunotherapy in thymic malignancies: a unique case of a durable and complete response upon an immune checkpoint inhibitor 89
Case Report: Detection of a Novel Germline PALB2 Deletion in a Young Woman With Hereditary Breast Cancer: When the Patient's Phenotype History Doesn't Lie 89
Immunological signature of patients with thymic epithelial tumors and Good syndrome 86
Under-reporting of subjective symptoms and its prognostic value: a pooled analysis of 12 cancer clinical trials 85
miRNAs in the Box: Potential Diagnostic Role for Extracellular Vesicle-Packaged miRNA-27a and miRNA-128 in Breast Cancer 82
Statin use and survival in patients with metastatic castrationresistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: The international retrospective observational STABEN study 77
Immunocytometric analysis of patients with thymic epithelial tumors revealed that COVID-19 vaccine booster strongly enhanced the immune response 77
Analysis of circulating extracellular vesicle derived microRNAs in breast cancer patients with obesity: a potential role for Let-7a 71
Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study 54
Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis 48
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer 38
Insights on the association of anthropometric and metabolic variables with tumor features and genomic risk in luminal early breast cancer: Results of a multicentric prospective study 22
Glucocorticoid Receptor and Ovarian Cancer: From Biology to Therapeutic Intervention 22
Management of Autoimmune Conditions Associated With Thymic Epithelial Tumors 18
The European Reference Network: the keystone for the management of rare thoracic cancers 16
Circulating tumor DNA clearance as a predictive biomarker of pathologic complete response in patients with solid tumors treated with neoadjuvant immune checkpoint inhibitors: a systematic review and meta-analysis 15
Multidisciplinary approach for rare thoracic tumors during COVID-19 pandemic 15
Circulating tumor DNA in early-stage triple-negative breast cancer: clinical landscape and key open challenges 12
Ductal Carcinoma In Situ 10
Totale 5.748
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.450
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.450
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021103 0 0 0 0 0 16 17 9 24 1 18 18
2021/2022215 6 3 11 7 2 5 11 9 7 22 70 62
2022/2023397 34 34 14 17 36 39 14 43 51 78 21 16
2023/2024407 15 53 59 39 19 57 6 50 8 5 52 44
2024/20252.026 63 69 4 54 70 134 201 132 118 230 777 174
2025/20262.498 418 307 484 375 715 199 0 0 0 0 0 0
Totale 5.748